Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Surgery
Share your love
AAO 2026 Highlights Hospital Ophthalmology Coverage Gaps and Growing Reimbursement Pressures
Access to hospital-based eye care and reimbursement were policy topics at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting, where ophthalmology leaders described a retrospective review of 747 eye-related transfers from 25 hospitals in the New York area. The…
Atsena Therapeutics Reports Preliminary LIGHTHOUSE Results for ATSN-201 Gene Therapy in X-Linked Retinoschisis
Atsena Therapeutics reported preliminary findings on 7 October 2026 from Parts A and B of the LIGHTHOUSE trial of ATSN-201, an investigational gene therapy for X-linked retinoschisis (XLRS). The company reported improvements in retinal structure and selected functional measures, including…
Eyestem Research Presents Eyecyte-RPE Cell Therapy Data in Geographic Atrophy at EURETINA 2026
Eyestem Research presented clinical data for Eyecyte-RPE, an investigational retinal pigment epithelium (RPE) cell therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD), at EURETINA 2026 in Vienna. A mean best-corrected visual acuity (BCVA) gain of about…
Sight Sciences Introduces OMNI Ultra Surgical System at AAO 2026
Sight Sciences announced on October 1, 2026 that it would debut its OMNI Ultra Surgical System, the latest version of its implant-free minimally invasive glaucoma surgery (MIGS) platform, at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting in New…
SpyGlass Pharma Acquires Advanced Vision Science to Advance Drug-Eluting IOL Technology for Glaucoma
SpyGlass Pharma announced on October 1, 2026 that it has acquired Advanced Vision Science (AVS), its existing intraocular lens (IOL) manufacturer, for about $13 million. The deal gives SpyGlass direct control over a key component of its investigational BIM-IOL system,…
MacTel Decoded: Rethinking Conventional Approaches with Novel Neuroprotective Strategies | Ophthalmology Times
Thanks for your interest in this podcast. Please read this important program information before listening. Episode Description In this podcast, experts Charles C. Wykoff, MD, PhD, FASRS; Jed H. Assam, MD, MS; Diana V. Do, MD; and Dante Pieramici, MD,…
International Glaucoma Symposium highlights the meeting point of practice and technology | Ophthalmology Times
The 2nd International Glaucoma Symposium underscores how AI and advanced imaging are becoming integral to modern glaucoma diagnosis and management. (Image credit: AdobeStock/OngCaLucK) The International Glaucoma Symposium was created to close the gap between cutting-edge research and real-world clinical decision-making…
FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials | Ophthalmology Times
FDA approval of YUVEZZI marks the first dual-agent, daily eye drop option for adults seeking non-invasive presbyopia treatment. (Image credit: Ophthalmology Times) The FDA has approved a fixed-dose ophthalmic combination of carbachol and brimonidine tartrate (YUVEZZI; Tenpoint Therapeutics) for the…
Myra Vision treats first patient in ADAPT trial of Calibreye TGT Surgical System | Ophthalmology Times
(Image Credit: AdobeStock/andrew_shots) Myra Vision has treated the first patient in its ADAPT clinical study evaluating the Calibreye TGT Surgical System in patients with glaucoma. The ADAPT trial is a prospective, multicenter, nonrandomized, open-label study enrolling 70 refractory glaucoma patients…
Dr. Mali’s top 5 predictions in ophthalmology for 2026 | Ophthalmology Times
From artificial intelligence to retinal care and postoperative protection, Joshua Mali, MD, FASRS, offers five predictions shaping ophthalmology in 2026. (Image credit: AdobeStock/Sam Efendi) It’s that exciting time of the year again when I reveal my top 5 predictions in…